GRCE
Grace Therapeutics, Inc.
Next earnings Jun 23, 2026 · consensus $-0.23 EPS
Last earnings +7.2% on 2026-06-18
$2.38
▲ +0.42%$2.38▼ -18.77%
over 1Y
L $2.10EODHDH $5.13
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.4%
1W+5.3%
1M+2.1%
3M-49.0%
YTD-35.0%
1Y-18.8%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy
Conservative balance sheet (liabilities/equity 0.04x); but unprofitable (net margin -7.8%).
Revenue (FY2022) $100M · FY2022
Grace Therapeutics, Inc. shows $100M in FY2022 revenue, a -7.8% net margin, and -12.2% ROE.
Financials · annual, by fiscal year
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | $100M | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$15.6M | -$52.2M | -$12.9M | -$16.7M | -$11.1M |
| Net income | -$9.82M | -$42.4M | -$12.9M | -$9.57M | -$7.79M |
| Diluted EPS | -$0.27 | -$5.71 | -$1.35 | -$0.79 | -$0.47 |
| Net margin | -9.8% | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$21.8M
EV / EBITDA—
EV / Sales0.2
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-20.1%
FCF yield—
Quality & risk
ROIC (est.)-13.7%
Free cash flow—
Total debt—
Net cash$17.0M
Altman Z-Score4.85 safe
Piotroski F-Score1/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+17.7%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — restated periodic report (2025-11-17). Worth a closer look.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-182026-06-18open ↗8-KPeriod ending 2026-06-182026-06-18open ↗10-KPeriod ending 2026-03-312026-06-18open ↗8-KPeriod ending 2026-06-012026-06-05open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-04-27open ↗8-KPeriod ending 2026-04-272026-04-27open ↗8-KPeriod ending 2026-04-232026-04-23open ↗SCHEDULE 13G/AFiling2026-02-17open ↗SCHEDULE 13G/AFiling2026-02-13open ↗8-KPeriod ending 2026-02-122026-02-12open ↗10-QPeriod ending 2025-12-312026-02-12open ↗
Frequently asked
- Is Grace Therapeutics, Inc. (GRCE) a buy?
- GRCE currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.04x); but unprofitable (net margin -7.8%).
- What is Grace Therapeutics, Inc.'s quality score?
- GRCE scores 62.529411764705884/100 (grade C+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001444192, latest 10-K filed 2026-06-18) · EODHD · as of 6/22/2026, 9:46:36 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.